drug substances and products. The aim is to ensure method specificity, precision, and robustness in line with ICH Q1A and Q2(R1) guidelines.

2. Scope

This SOP applies to all stability-indicating method development activities conducted by the Analytical Method Development (AMD) department for both new drug substances and drug products at all stages of development.

3. Responsibilities

• Analytical Scientist: Designs, executes, and optimizes SIMs and documents all development experiments.
• Method Validation Analyst: Assesses the developed method for specificity, linearity, precision, accuracy, and robustness.
• QA Reviewer: Reviews experimental data and ensures compliance with applicable regulatory guidelines.
• Documentation Officer: Maintains controlled records of the development protocol and reports.

4. Accountability

The Head of AMD is accountable for approving method development plans, reviewing final method development reports, and ensuring timely validation and implementation of the developed methods.

5. Procedure

5.1 Literature and Regulatory Review

1. Perform a comprehensive literature review to identify existing analytical methods for the API.
2. Refer to ICH Q1A (R2), ICH Q2(R1), and FDA guidance documents.
3. Evaluate known degradation pathways and product-specific degradation mechanisms.

5.2 Selection of Analytical Technique

1. Based on API characteristics, select appropriate techniques such as HPLC, UPLC, GC, UV, or LC-MS/MS.
2. Prioritize techniques capable of detecting minor impurities and degradation products with high sensitivity.

5.3 Stress Studies (Forced Degradation)

1. Conduct forced degradation studies as per ICH Q1A to generate degradation products.
2. Include the following stress conditions:
   • Acid hydrolysis
   • Base hydrolysis
   • Oxidation
   • Thermal degradation
   • Photolysis
3. Ensure 10–30% degradation to mimic real-time breakdown pathways.
4. Document all degradation conditions and observations in the stress study log (Annexure-1).

5.4 Method Development

1. Optimize chromatographic conditions: column type, mobile phase, pH, flow rate, temperature, detection wavelength.
2. Achieve baseline resolution between the API and all degradation peaks (Rs ≥ 2.0).
3. Develop system suitability criteria including retention time (RT), tailing factor, resolution, and theoretical plates.

5.5 Specificity and Peak Purity Testing

1. Use diode-array detection (DAD) or mass spectrometry to verify peak purity.
2. Confirm that the API peak is spectrally homogeneous and free from co-eluting degradation products.

5.6 Documentation

1. Prepare a detailed Method Development Report including:
   • Method development rationale
   • Chromatograms for each optimization step
   • Stress degradation profiles
   • System suitability data
   • Conclusion and next steps (e.g., validation plan)

5.7 Archival and Reporting

1. Ensure all method development data is logged in controlled notebooks or electronic records.
2. Submit development report to QA for review and approval.
3. Archive the approved report with unique ID and metadata for traceability.

6. Abbreviations

• API: Active Pharmaceutical Ingredient
• SIM: Stability-Indicating Method
• DAD: Diode Array Detector
• Rs: Resolution

7. Documents

1. Annexure-1: Stress Study Log Template
2. Annexure-2: Method Development Report Template
3. Annexure-3: System Suitability Criteria Checklist

8. References

• ICH Q1A(R2) – Stability Testing of New Drug Substances and Products
• ICH Q2(R1) – Validation of Analytical Procedures
• FDA Guidance for Industry – Stability Testing of Drug Substances and Products

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name	Ritika Sharma	Neeraj Verma	Dr. Smita Kulkarni
Designation	Analyst – AMD	QA Officer	Head – AMD
Department	Analytical Method Development	Quality Assurance	Analytical Method Development

11. Annexures

Annexure-1: Stress Study Log Template

Condition	Time (hrs)	Observed Degradation (%)	Remarks
Acid (1N HCl)	2	18.4	Major peak at RT 7.6 min

Annexure-2: Method Development Report Template

To include sections: Objective, Materials and Methods, Optimization Strategy, Stress Study Data, Peak Purity Evaluation, and Conclusion.

Annexure-3: System Suitability Criteria Checklist

• Resolution between API and closest peak ≥ 2.0
• Tailing factor ≤ 2.0
• Theoretical plates ≥ 2000
• RSD of replicate injections ≤ 2.0%

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
01/06/2025	2.0	Updated to include expanded stress testing and reporting guidelines	Annual Review	Dr. Smita Kulkarni
10/08/2022	1.0	Initial version	New SOP	QA Head